Creyon Bio is reinventing drug development from the ground up and making on-demand oligonucleotide therapeutics possible. With powerful, purpose-built data sets to drive efficient creation of machine learning models, we engineer oligonucleotide-based medicines (OBMs) for safe, precise gene-centric therapies with unprecedented speed and predictable efficacy and safety. It’s a groundbreaking modular approach that slashes costs for new medicines whether treating disease impacting one patient or millions.
With partnerships ranging from industry to patient advocates and policymakers, we are working together to build a faster, more cost-effective path to medicines for those who need them most.
Our multidisciplinary team of chemists, biologists, and computational scientists is tackling the drug development challenge from all angles.
Are you ready to be a Creyoneer? Build a faster, more streamlined, and more equitable process for creating new medicines with us.
Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development Collaboration
SAN DIEGO, CA, April 29, 2025 — Creyon Bio, Inc. (“Creyon”) today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the discovery, development and commercialization of novel RNA-targeted oligonucleotide (oligo) therapies for a broad range of diseases. As a part of the collaboration, Creyon will leverage its industry-first AI-Powered Oligo Engineering Engine to design and optimize new drug candidates for Lilly’s named targets on time scales not previously achievable in nucleic acid drug development.
Creyon Bio Appoints Industry Leader, Serge Messerlian as CEO, Leveraging Decades of Company Building and Strategic Collaborations
SAN DIEGO, CA, April 23, 2025 — Creyon Bio, Inc. (“Creyon”) today announced the appointment of industry leader, Serge Messerlian as Chief Executive Officer, effective immediately. Mr. Messerlian brings Creyon Bio a track record in both multinational pharmaceutical and biotechnology leadership as well as company building and strategic collaborations across a range of disease areas including hematology, oncology, immunology, and rare diseases as well as novel technology platforms.
Creyon Bio Publishes New Research Establishing Rigorous Quantification Methods of Off-target Analysis in Oligonucleotide Drug Design
Creyon Bio, Inc, a drug development company focused on transforming nucleic-acid medicine drug discovery to drug engineering, published new research greatly increasing their ability to engineer Oligonucleotide-Based Medicines (OBMs) with minimal off-target effects, which will help us evaluate molecules with a higher standard of precision and live up to the full potential of the “super-modality” of oligonucleotide-based medicines.
Creyon Bio to Present Clinical Data on Rapid AI-Enabled Engineering of Oligonucleotide-Based Medicines at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
Creyon Bio, Inc. (“Creyon”), a clinical stage drug development company that engineers Oligonucleotide-Based Medicines (OBMs) with industry-leading efficiency creating novel, best-in-class gene-centric medicines to treat rare and common diseases, today announced encouraging clinical data highlighting the use of its custom designed data set paired with artificial intelligence (AI) to rapidly engineer an investigational antisense oligonucleotide (ASO) therapy.
This website uses cookies to enhance your experience. Some are essential for site functionality, while others help us analyze and improve your usage experience. Please review your options and make your choice.
If you are under 16 years old, please ensure that you have received consent from your parent or guardian for any non-essential cookies.
Your privacy is important to us. You can adjust your cookie settings at any time. For more information about how we use data, please read our privacy policy. You may change your preferences at any time by clicking on the settings button below.
Note that if you choose to disable some types of cookies, it may impact your experience of the site and the services we are able to offer.
Some required resources have been blocked, which can affect third-party services and may cause the site to not function properly.
This website uses cookies to enhance your browsing experience and ensure the site functions properly. By continuing to use this site, you acknowledge and accept our use of cookies.
